Results 281 to 290 of about 131,732 (302)

Higher Rates of Viral Suppression with Nonnucleoside Reverse Transcriptase Inhibitors Compared to Single Protease Inhibitors Are Not Explained by Better Adherence

HIV Clinical Trials, 2004
Elise Riley, David Bangsberg, Sheri Weiser   +2 more
exaly  

Lead Optimization of Diarylpyrimidines as Non‐nucleoside Inhibitors of HIV‐1 Reverse Transcriptase

ChemMedChem, 2010
Christophe Pannecouque, Erik De Clercq, Fen-Er Chen   +2 more
exaly  

Specific HIV-1 Reverse Transcriptase Inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry, 1992
Erik De Clercq, Zeger Debyser, K Andries   +2 more
exaly  

Virtual screening studies on HIV-1 reverse transcriptase inhibitors to design potent leads

European Journal of Medicinal Chemistry, 2011
Barij Nayan Sinha, Rambabu Gundla, S Vadivelan   +2 more
exaly  

Non‐nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability

Journal of the International AIDS Society, 2013
José-Esteban Peris
exaly  

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

Lancet, The, 1999
Johannes A Romijn, , Kees Brinkman
exaly  

Non-nucleoside reverse transcriptase inhibitors

2007
DUNN JAMES PATRICK, SWALLOW STEVEN, SWEENEY ZACHARY KEVIN   +2 more
openaire   +2 more sources

Comparative study of non nucleoside inhibitors with HIV-1 reverse transcriptase based on 3D-QSAR and docking

SAR and QSAR in Environmental Research, 2003
H F Chen, J P Doucet, X J Yao
exaly  

REVERSE TRANSCRIPTASE INHIBITORS

2009
SHAGINIAN ALEKSANDR, OUK SAMEDY, VERNIER JEAN-MICHEL, PINKERTON ANTHONY B   +3 more
openaire   +1 more source

Reverse transcriptase inhibitors and antiviral agents

1994
UCHINO KEIJIRO, MIZUNO TAKASHI, MURAKAMI SACHIE, NAKASHIMA HIDEKI, YAMAMOTO NAOKI HARAMACHI-JUTAK, OGAWARA HIROSHI   +5 more
openaire   +2 more sources